Akira Tani
Kusatsu, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Impact of glucagon-like peptide-1 receptor agonists with guideline-directed medical therapy in patients with heart failure with reduced ejection fraction and type 2 diabetes.
Journal: Diabetes research and clinical practice
Published: May 18, 2026
Oral semaglutide and survival in heart failure with preserved ejection fraction and type 2 diabetes.
Oral semaglutide and survival in heart failure with preserved ejection fraction and type 2 diabetes.
Journal: Diabetes, obesity & metabolism
Published: October 14, 2025
Combination therapy with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in heart failure patients with type 2 diabetes.
Journal: BMJ open diabetes research & care
Published: June 28, 2025
Comparative Outcomes of Tirzepatide and Semaglutide in Patients With Heart Failure With Preserved Ejection Fraction and Type 2 Diabetes.
Journal: Journal of cardiac failure
Published: June 10, 2025
Comparative cardiovascular outcomes of semaglutide to dulaglutide in patients with type 2 diabetes.
Journal: Scientific reports
Published: April 15, 2025
Cardiovascular outcomes and safety of semaglutide in non-overweight populations with type 2 diabetes: a comparison with dipeptidyl peptidase 4 inhibitors.
Journal: European heart journal. Quality of care & clinical outcomes
Published: March 02, 2025
Comparative Outcomes of Glucagon-Like Peptide-1 Receptor Agonists to Dipeptidyl Peptidase 4 Inhibitors in Patients With Heart Failure and Type 2 Diabetes.
Journal: Journal of the American Heart Association
Published: February 08, 2025
Showing 1-8 of 8
Last Updated: 09/26/2026